Patent application number | Description | Published |
20090176787 | Crystalline Forms of lamotrigine - The invention is directed to novel crystalline forms of lamotrigine. These novel crystalline forms of lamotrigine have improved dissolution and in-vivo absorption profile, as compared to pure lamotrigine. These novel crystalline forms of lamotrigine provide a substantial increase in the blood concentration of lamotrigine, as compared to pure lamotrigine when administered to a subject. These novel crystalline forms of lamotrigine also provide a slower, steady build up of lamotrigine blood concentration suitable for sustained release of lamotrigine in-vivo, as compared to pure lamotrigine. | 07-09-2009 |
20090203680 | In vivo studies of crystalline forms of meloxicam - The invention is directed to novel crystalline forms of meloxicam. These novel crystalline forms of meloxicam have improved bioavailability, an enhanced rate of dissolution and shorter time to C | 08-13-2009 |
20110028435 | CRYSTALLIZATION METHOD AND BIOAVAILABILITY - Preparation, in-vitro and in vivo characterization of novel forms of (1-hydroxy-2-imidazol-1-yl-1-phosphono-ethyl)phosphonic acid, suitable for pharmaceutical compositions in drug delivery systems for humans. | 02-03-2011 |
20120046297 | CRYSTALIZATION OF PHARMACEUTICAL COMPOUNDS - Novel crystalline forms of tadalafil suitable for pharmaceutical compositions in drug delivery systems for humans. | 02-23-2012 |
20120149692 | In Vivo Studies of Crystalline Forms of Meloxicam - The invention is directed to novel crystalline forms of meloxicam. These novel crystalline forms of meloxicam have improved bioavailability, an enhanced rate of dissolution and shorter time to C | 06-14-2012 |
20120190647 | NOVEL ORAL FORMS OF A PHOSPHONIC ACID DERIVATIVE - Novel solution complexes of zoledronic acid are described which give rise to improved properties of zoledronic acid. The invention includes aqueous solution and molecular complexes of zoledronic acid with and optical isomers of asparagine, histidine, arginine and proline as well as pharmaceutical complexes containing them and methods of treatment using them. | 07-26-2012 |
20130035315 | CRYSTALLIZATION METHOD AND BIOAVAILABILITY - Preparation and in vitro and in vivo characterization of novel forms of active pharmaceutical ingredients, suitable for pharmaceutical compositions in drug delivery systems for humans. | 02-07-2013 |
20130316982 | NOVEL CRYSTALLINE FORMS - Preparation and characterization of novel forms of (1-hydroxy-2-imidazol-1-yl-1-phosphono-ethyl) phosphonic acid, suitable for pharmaceutical compositions in drug delivery systems for humans. | 11-28-2013 |
20140057875 | CRYSTALLIZATION METHOD AND BIOAVAILABILITY - Preparation, in-vitro and in vivo characterization of novel forms of (1-hydroxy-2-imidazol-1-yl-1-phosphono-ethyl)phosphonic acid, suitable for pharmaceutical compositions in drug delivery systems for humans. | 02-27-2014 |
20140100233 | CRYSTALIZATION OF PHARMACEUTICAL COMPOUNDS - Novel crystalline forms of tadalafil suitable for pharmaceutical compositions in drug delivery systems for humans. | 04-10-2014 |
20140107076 | CRYSTALLIZATION METHOD AND BIOAVAILABILITY - Preparation, in-vitro and in vivo characterization of novel forms of (1-hydroxy-2-imidazol-1-yl-1-phosphono-ethyl)phosphonic acid, suitable for pharmaceutical compositions in drug delivery systems for humans. | 04-17-2014 |